SPOTLIGHT -
EP. 1: Treating Intermediate Risk Individuals with Breast Cancer
EP. 2: Genomic Testing in Breast Cancer
EP. 3: Managing Luminal A and Luminal B Breast Cancer
EP. 4: Appropriate Duration of Endocrine Therapy in Breast Cancer
EP. 5: The Role of Fulvestrant in Metastatic HR+ Breast Cancer
EP. 6: Review of Clinical Data on Palbociclib in Breast Cancer
EP. 7: Managing Mouth Sores in Patients with Breast Cancer
EP. 8: First-Line Treatment of HER2-Positive MBC
EP. 9: MARIANNE and BOLERO-1 Trial Results in Breast Cancer
EP. 10: Neoadjuvant Therapy for HER2+ Breast Cancer
EP. 11: Post-Adjuvant Breast Cancer Treatment
EP. 12: Neoadjuvant Treatment in Triple-Negative Breast Cancer
EP. 13: Analyzing the Use of Eribulin in Metastatic Breast Cancer
EP. 14: Immunotherapy in Breast Cancer
EP. 15: Prospects in the Management of Breast Cancer
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
